Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/1397| Comparison of serologic assays for Middle East respiratory syndrome coronavirus | |
| Harvey, R Mattiuzzo, G Hassall, M Sieberg, A Müller, M Drosten, C Rigsby, P Oxenford, C Caly, L Li, C Zhao, L Tan, W Peiris, M Perera, M Drosten, C Kang, C Wang, J Haagmans, B Okba, N Gopal, R Myhill, S Thornburg, N | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| Middle East respiratory syndrome coronavirus (MERS-CoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results. | |
| Emerging Infectious Diseases | |
| 2019 | |
| Preimpreso | |
| https://coronavirus.1science.com/item/6bb3c65d9a54a6e9e37968aca075e69f798c1462 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 108521.pdf | 816.46 kB | Adobe PDF | Visualizar/Abrir |